ArticleDiscover oncology2026
Construction of chronic inflammation and mitochondrial energy metabolism-associated predictive and therapeutic models for lung adenocarcinoma patients.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) remains the most common subtype of non–small cell lung cancer with poor survival. Dysregulation of mitochondrial energy metabolism (MEM) can be considered as major driver for LUAD pathogenesis among Chronic obstructive pulmonary disease (COPD) patients. Hence, deeper understanding of MEM carcinogenic role for LUAD patients can provide novel insights into LUAD pathogenesis for COPD patients.
methodsBy employing integrative bioinformatic approaches, such as Limma and WGCNA in LUAD bulk profile (GSE32863), we first identified COPD and MEM (CM)-associated DEGs for LUAD patients, and these DEGs can divide LUAD patients from TCGA-LUAD cohort into 2 risk groups. Next, Lasso-cox regression and multi-variate cox regression identified CM-associated predictive model and hub gene for LUAD patients both in TCGA-LUAD cohort and GSE13213. Indeed, hub gene molecular and immune characters were estimated at LUAD bulk level (TCGA-LUAD cohort) and single-cell level (GSE203360). Besides, drug sensitivity and molecular docking analysis confirmed potential therapeutic agent targeting hub gene for the treatment of LUAD.
results8 CM-associated gene signatures can divide LUAD patients into 2 molecular subgroups and guide the prognostic model construction for LUAD patients. TPI1 can be considered as CM-associated hub gene involved in LUAD progression. 17-AAG can be considered as drug reproposing framework for the treatment of LUAD.
conclusionThis study first highlighted the predictive and therapeutic potentials of CM, and highlighted TPI1 pathogenic role for LUAD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.